Clinical Trial Update: Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

A long-term extension of a Phase 3 trial evaluating ponesimod 20 mg in relapsing multiple sclerosis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• PONVORY (PONESIMOD)

Snippet

Sponsor: Actelion | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2025-02-21